Table 1

Baseline and procedural details according to P2Y12-receptor inhibitor

Baseline and procedural characteristicsPrasugrel (n=1244)Ticagrelor (n=811)P valueClopidogrel
(n=1648)
Prasugrel (n=1244)P valueTicagrelor (n=811)Clopidogrel (n=1648)P value
Age in years, median (IQR)61 (17)63 (19) < 0.01 65 (21)61 (17) < 0.01 63 (19)65 (21) < 0.01
Male, n (%)941 (75.6)587 (72.4)0.101178 (71.5)941 (75.6) 0.01 587 (72.4)1178 (71.5)0.64
White, n (%)1061 (85.3)707 (87.2)0.231388 (84.2)1061 (85.3)0.43707 (87.2)1388 (84.2) 0.05
Diabetes mellitus, n (%)152 (12.2)133 (16.4) < 0.01 235 (14.3)152 (12.2) 0.05 133 (16.4)235 (14.3)0.37
Current/ex-smoker, n (%)885 (71.1)510 (62.9) < 0.01 1070 (64.9)885 (71.1) < 0.01 510 (62.9)1070 (64.9)0.54
Hypertension, n (%)424 (34.1)317 (39.1) < 0.01 688 (41.7)424 (34.1) < 0.01 317 (39.1)688 (41.7) < 0.01
Hypercholesterolaemia, n (%)365 (29.3)269 (33.2) < 0.01 524 (31.8)365 (29.3)0.15269 (33.2)524 (31.8) < 0.01
Renal insufficiency, n (%)15 (1.2)16 (2.0) < 0.01 66 (4.0)15 (1.2) < 0.01 16 (2.0)66 (4.0) < 0.01
Previous MI, n (%)122 (9.8)101 (12.5) < 0.01 237 (14.4)122 (9.8) < 0.01 101 (12.5)237 (14.4) 0.02
Peripheral/cerebrovascular disease, n (%)53 (4.3)54 (6.7) < 0.01 180 (10.9)53 (4.3) < 0.01 54 (6.7)180 (10.9) < 0.01
Cardiogenic shock, n (%)36 (2.9)59 (7.3) < 0.01 75 (4.6)36 (2.9) 0.02 59 (7.3)75 (4.6) < 0.01
Anterior ST-elevation MI, n (%)542 (43.6)320 (39.5)0.07673 (40.8)542 (43.6)0.14320 (39.5)673 (40.8)0.51
Call-to-balloon time in minutes, median (IQR)122 (43)125 (52) 0.02 142 (79)122 (43) < 0.01 125 (52)142 (79) < 0.01
Door-to-balloon time in minutes, median (IQR)51 (30)48 (28) < 0.01 51 (33)51 (30)0.8348 (28)51 (33) < 0.01
Radial access, n (%)876 (70.4)663 (81.8) < 0.01 843 (51.2)876 (70.4) < 0.01 663 (81.8)843 (51.2) < 0.01
Multivessel PCI, n (%)100 (8.0)63 (7.8)0.83160 (9.7)100 (8.0)0.1263 (7.8)160 (9.7)0.12
Drug-eluting stents, n (%)785 (63.1)669 (82.5) < 0.01 773 (46.9)785 (63.1) < 0.01 669 (82.5)773 (46.9) < 0.01
Glycoprotein IIb/IIIa antagonist, n (%)197 (15.8)88 (10.9) < 0.01 302 (18.3)197 (15.8)0.0888 (10.9)302 (18.3) < 0.01
Bivalirudin, n (%)1202 (96.6)771 (95.1)0.081532 (93.0)1202 (96.6) < 0.01 771 (95.1)1532 (93.0) 0.04
Aspiration thrombectomy, n (%)917 (73.7)621 (76.8)0.231053 (63.9)917 (73.7) < 0.01 621 (76.8)1053 (63.9) < 0.01
Postprocedural TIMI 3 flow, n (%)1121 (90.1)737 (90.9)0.241410 (85.6)1121 (90.1) < 0.01 737 (90.9)1410 (85.6) < 0.01
  • Data are expressed in median (IQR) or n (%) as described.

  • MI, myocardial infarction; PCI, percutaneous coronary intervention; TIMI, thrombolysis in MI.